Article
BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
Human pathology - 1 Apr 2016
Mudaliar Kumaran, Tetzlaff Michael T, Duvic Madeleine, Ciurea Ana, Hymes Sharon, Milton Denái R, Tsai Kenneth Y, Prieto Victor G, Torres-Cabala Carlos A, Curry Jonathan L
Abstract excerpt
Newly appearing or changing melanocytic lesions (MLs) are a recently reported toxicity of BRAF inhibitor (BRAFi) therapy. Morphologically, MLs associated with BRAFi therapy (BRAFi-MLs) may demonstrate alarming features of melanoma with an epithelioid cell phenotype with notable cytologic atypia. We sought to characterize the clinicopathological and molecular features of BRAFi-MLs. A retrospective review over a...
Topics
- Adult
- Aged
- Antineoplastic Agents
- Biopsy
- Cyclin D1
- Female
- Humans
- Immunohistochemistry
- Male
- Melanocytes
- Melanoma
- Middle Aged
- Mutation
- Neoplasms, Second Primary